Sanofi (NASDAQ:SNY) Position Lifted by ST Germain D J Co. Inc.

ST Germain D J Co. Inc. raised its stake in shares of Sanofi (NASDAQ:SNY) by 9.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,060 shares of the company’s stock after acquiring an additional 665 shares during the quarter. ST Germain D J Co. Inc.’s holdings in Sanofi were worth $389,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares during the last quarter. Franklin Resources Inc. boosted its stake in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after acquiring an additional 395,744 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Sanofi by 8.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after acquiring an additional 246,224 shares during the last quarter. Federated Hermes Inc. boosted its stake in Sanofi by 26.5% during the 2nd quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after acquiring an additional 673,172 shares during the last quarter. Finally, Natixis Advisors LLC raised its holdings in shares of Sanofi by 4.1% during the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after purchasing an additional 114,133 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Down 1.0 %

SNY stock opened at $48.73 on Friday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The firm’s 50-day simple moving average is $48.70 and its 200 day simple moving average is $52.07. The stock has a market cap of $123.67 billion, a PE ratio of 24.86, a price-to-earnings-growth ratio of 1.23 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter last year, the company earned $2.55 EPS. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, sell-side analysts predict that Sanofi will post 4.06 EPS for the current year.

Wall Street Analyst Weigh In

SNY has been the topic of a number of research reports. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.